Elanco Animal Health
ELAN · New York Stock Exchange
☆ Follow
Shareholder advocacy aimed at Elanco Animal Health
1 recorded campaign from 1 organization.
Coordinates an Animal Pharmaceuticals engagement with the largest listed veterinary-drug makers on antimicrobial resistance
Investor coalition presses seven of the largest publicly-listed animal-pharma companies for transparency on antibiotic manufacturing/marketing/sales and antimicrobial-resistance risk management. Progress report "From Farms to Forks" published May 2024; investor guide co-developed with MSCI Sustainability Institute and IAAMR in 2024.
What shareholders voted on
From Elanco Animal Health’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.
2026
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below | Say on pay | 82% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2026, by the votes set forth in the table below | Auditor | 99.5% | Passed | |
| Election of Lawrence Kurzius | Director | 94.7% | Passed | |
| Election of Paul Herendeen | Director | 94.3% | Passed | |
| Election of Kirk McDonald | Director | 94.2% | Passed | |
| Election of Kapila K. Anand | Director | 80.3% | Passed | |
| Election of Michael Harrington | Director | 79.8% | Passed |
2025
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below | Say on pay | 53.5% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2025, by the votes set forth in the table below | Auditor | 99.3% | Passed | |
| Election of Paul Herendeen | Director | 94.5% | Passed | |
| Election of Kapila K. Anand | Director | 65.9% | Passed |
2024
2023
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below | Say on pay | 81% | Passed | |
| The Amended and Restated Elanco Animal Health Incorporated Employee Stock Purchase Plan, by the votes set forth in the table below | Company proposal | 99.9% | Passed | |
| The Amended and Restated 2018 Elanco Animal Health Incorporated Stock Plan, by the votes set forth in the table below | Company proposal | 96.1% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2023, by the votes set forth in the table below | Auditor | 99.9% | Passed | |
| Election of Kirk P. McDonald | Director | 61.4% | Passed | |
| Election of Michael J. Harrington | Director | 59.7% | Passed | |
| Election of Deborah T. Kochevar | Director | 37.9% | Failed | |
| Election of R. David Hoover | Director | 28.8% | Failed |
2022
2021
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of named executive officers, by the votes set forth in the table below | Say on pay | 96.7% | Passed | |
| The Amended and Restated 2018 Elanco Stock Plan, including an amendment to increase the number of shares authorized for issuance thereunder by | Company proposal | 97.1% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s principal independent auditor for 2021, by the votes set forth in the table below | Auditor | 100% | Passed | |
| Election of William F. Doyle | Director | 78.9% | Passed | |
| Election of Jeffrey N. Simmons | Director | 63% | Passed | |
| Election of Art A. Garcia | Director | 53.7% | Passed | |
| Election of Denise Scots-Knight | Director | 53.5% | Passed |
2020
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of named executive officers, by the votes set forth in the table below | Say on pay | 95% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s principal independent auditor for 2020, by the votes set forth in the table below | Auditor | 100% | Passed | |
| Election of Michael J. Harrington | Director | 61% | Passed | |
| Election of Deborah T. Kochevar | Director | 59.1% | Passed | |
| Election of Kirk P. McDonald | Director | 58.9% | Passed |
2019
| Item | Kind | Asked for by | Support | Outcome |
|---|---|---|---|---|
| By non-binding vote, the compensation of named executive officers, by the votes set forth in the table below | Say on pay | 98.1% | Passed | |
| The appointment of Ernst & Young LLP as Elanco’s principal independent auditor for 2019, by the votes set forth in the table below | Auditor | 100% | Passed | |
| Election of Lawrence E. Kurzius | Director | 99.9% | Passed | |
| Election of John P. Bilbrey | Director | 99.9% | Passed | |
| Election of Kapila K. Anand | Director | 99.9% | Passed | |
| Election of R. David Hoover | Director | 53.4% | Passed |
Proxy statements and vote results
Straight from Elanco Animal Health’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.
| Year | Filing | Filed |
|---|---|---|
| 2026 | Vote results | 2026-05-27 |
| 2026 | Proxy statement | 2026-04-08 |
| 2025 | Vote results | 2025-05-21 |
| 2025 | Proxy statement | 2025-03-27 |
| 2024 | Vote results | 2024-06-04 |
| 2024 | Proxy statement | 2024-04-19 |
| 2023 | Vote results | 2023-05-22 |
| 2023 | Proxy statement | 2023-04-06 |
| 2022 | Vote results | 2022-05-19 |
| 2022 | Proxy statement | 2022-04-06 |
| 2021 | Vote results | 2021-05-21 |
| 2021 | Proxy statement | 2021-03-25 |
| 2020 | Vote results | 2020-05-22 |
| 2020 | Proxy statement | 2020-04-08 |
| 2019 | Vote results | 2019-05-09 |
| 2019 | Proxy statement | 2019-04-03 |
Do you represent Elanco Animal Health? Claim this profile to respond to the campaigns listed here.